Skip to main content
B

BOTANIX PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · BOT ISIN · AU000000BOT2 ASX Manufacturing
Filings indexed 1,206 across all filing types
Latest filing 2023-11-22 Regulatory Filings
Country AU Australia
Listing ASX BOT

About BOTANIX PHARMACEUTICALS LTD

https://botanixpharma.com/

Botanix Pharmaceuticals Ltd is a clinical-stage pharmaceutical company focused on the development and commercialization of novel topical treatments for serious skin conditions. The company utilizes its proprietary Permetrex™ skin delivery technology, which is designed to improve the delivery of active ingredients through the skin. Its primary product, Sofdra™ (sofpironium bromide), is an FDA-approved prescription topical gel for the treatment of primary axillary hyperhidrosis. The company's research and development pipeline also includes clinical-stage candidates for the treatment of acne, rosacea, and atopic dermatitis. Botanix aims to address significant unmet medical needs in dermatology by providing innovative therapeutic solutions with enhanced safety and efficacy profiles.

Recent filings

Filing Released Lang Actions
Trading Halt 2 pages 554.6KB
Regulatory Filings
2023-11-22 English
Annual General Meeting - Chairman's Address 3 pages 117.7KB
Regulatory Filings
2023-11-07 English
Annual General Meeting Presentation 19 pages 4.0MB
Regulatory Filings
2023-11-07 English
Results of Annual General Meeting 2 pages 164.1KB
Regulatory Filings
2023-11-07 English
September 2023 Quarterly Activities Report and Appendix 4C 10 pages 742.8KB
Regulatory Filings
2023-10-30 English
Investor Presentation and Investor Meetings 26 pages 2.8MB
Regulatory Filings
2023-10-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.